Longzen Receives First GMP Compliance Notification for Active Pharmaceutical Ingredient Gadobutrol

Shandong, China--We are proud to announce that Longzen has officially received its first Drug GMP Compliance Notification. This milestone certifies that our manufacturing process for the active pharmaceutical ingredient Gadobutrol complies with Good Manufacturing Practice (GMP) standards.

The issuance of this notification marks the launch of full-scale production and commercial distribution of Gadobutrol, and represents a significant breakthrough in Longzen’s core business development. With this achievement, Longzen enters a new era of accelerated growth in the pharmaceutical industry.